Evaluation of Adherence, Persistence and Efficacy of Treatment With Alirocumab 300mg in Italy
Recruiting
Observational Study
Hypercholesterolaemia
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 – 80
- Sex
- Any
- Study type
- Observational
- Participants needed
- 1,500 (estimated)
- Sponsor
- Federico II University · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Evaluation of adherence, persistence and efficacy of treatment with alirocumab 300 mg in a real-life Italian population.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
\- Patients under alirocumab 300mg treatment.
Exclusion Criteria:
* Age \< 18 years o \> 80 years;
* Patients who refuse to participate and to sign informed consent.
Contacts